Sign up by: 01 January 2023
The drug being studied is called JNJ-63733657. All reference to the words "study drug" can mean JNJ-63733657 or non-active placebo. A placebo is an inactive substance used as a control in a clinical study, to determine whether and how well the investigational drug works. In this study, the placebo will be a liquid that looks exactly like the investigational drug and is given in the same way but that contains no active drug. The purpose of this study is to see if JNJ-63733657 is safe and useful for treating participants with Early Alzheimer's disease defined as prodromal and mild dementia due to Alzheimer's disease. JNJ-63733657 is a tau monoclonal antibody that is designed to bind to tau in the brain. Tau is a protein that builds up in the brain and may cause memory loss. This study will determine if this antibody may prevent the tau from spreading in the brain and slow cognitive decline.
Key Details
Study Sponsor: Study Sponsor: Janssen Research & Development, LLC
Location: In-person (Required at Toronto Western Hospital)
How Often: Monthly
Compensation: Yes ($50 per visit)
Contact: Behnaz Ghazanfari or Amy Obssi, Memory Clinic Research Coordinator
[email protected]
(416) 603-5910
Research Studies
Interested in participating in research studies? Scroll down to browse our current list.
Drug
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease
Drug
A Phase 3, multi-center, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy and safety of sodium oligomannate (GV-971) in treatment of mild to moderate Alzheimer's disease (GREEN MEMORY: GREen Valley 971 E
Sign up by: 31 December 2022
The purpose of the current study is to see whether the study drug, GV-971, improves AD symptoms, and how safe it is. The study will also look at what the body does to the study drug, such as how the body breaks down and uses the study drug and how it is removed from the body. This is known as pharmacokinetics. The study drug is currently approved for use in China for the treatment of mild to moderate AD. The study drug is made from a seaweed called brown algae. A specific sugar contained within the seaweed suppresses certain bacteria contained in the gut, which can cause harm to the brain, leading to AD. Approximately 2046 participants in around 200 study centers around the world will take part in this study.
Key Details
Study Sponsor: Sponsor of study is Shanghai Green Valley Pharmaceutical Co., Ltd.
Location: In-person (Required at Toronto Western Hospital)
How Often: Monthly
Compensation: Yes ($50 per visit)
Contact: Behnaz Ghazanfari, Memory Clinic Research Coordinator
[email protected]
416-603-5800 Ext.5910
Drug
Escitalopram for Agitation in Alzheimer's Disease (S-citAD) Study at Ontario Shores
Sign up by: 25 November 2023
The main goal of the S-citAD study is to assess the safety and efficacy of escitalopram (a drug) in combination with psychosocial intervention as a treatment for agitation in patients with Alzheimer's disease. It will also look at the predictors of relapse and response duration, in patients with Alzheimer's disease with agitation who improve with psychosocial intervention, as well as those who do not improve with psychosocial intervention. This 24-week trial (12 weeks treatment; 12 weeks follow-up) enrolls participants from real world settings such as outpatient and assisted living facilities.
Key Details
Study Sponsor: This study is funded by the National Institute on Aging (NIA)/ Johns Hopkins University.
Currently Enrolling: Individuals living in Whitby and the surrounding areas including the greater Toronto area
Location: In-person (Required at Ontario Shores Centre for Mental Health Sciences*) + Phone (Optional) + Internet (Optional)
*The majority of the visits during this study will be completed via phone or video calls. However, participants will be required to come to Ontario Shores Centre for Mental Health Sciences for 2 or 6 visits during the 15-week treatment period.
How Often: Monthly
Compensation: Yes (Participants will receive payment of $25 per visit*)
*This applies to the first two visits, as well as Week 3, Week 6, Week 9 and Week 12. For in-person visits, participants will receive payment at the end of the visit. For telephone/video contacts, participants will be emailed an electronic gift card/cheque by regular mail (Canada Post).
Contact: Elaina Niciforos, Lead Study Co-ordinator
905-430-4055 Ext. 6139
905-430-4055 Ext. 6423